Accuracy is everything when patient lives are at stake

  • >99.92% sensitivity / >99.99% specificity (1)
  • Technological innovations, several unique to Myriad, have been developed over 20 years with 2.5 million patients tested

Myriad’s myVision Variant Classification program is considered the gold standard in the industry

  • We employ over 30 medical professionals of varying disciplines who meet daily to classify and reclassify variants
  • We use 8 published and peer-reviewed methodologies, 2 unique to Myriad that have >99% PPV or NPV (2,3,4)
  • We classified over 10,000 variants in 2016, and sent over 400 reclassified results to providers every week
  • Lifetime commitment to classification: We will provide you and your patients an updated result if a variant is reclassified, no matter when the original testing occurred

Responsible Stewards of the data

  • Myriad is committed to protecting patient privacy and does not engage in activities that could compromise the privacy of an individual patient’s genetic information
  • Myriad will always share an individual patient’s genetic test results with the patient, their provider and anyone else the patient designates access to
  • Myriad shares data in a responsible fashion that respects patient privacy through peer-reviewed literature and scientific presentation, and is a founding member of the PROMPT registry
  • In a responsible effort to share data, Myriad has contributed more to the scientific literature via publication and presentation than any other hereditary cancer lab

What to know when discussing test results with patients:

Positive

  • A genetic mutation was found in 1 or more of the genes tested
  • The patient is at increased risk for cancer
  • A summary of medical management guidelines will be provided specific to the patient’s gene mutation(s)

Elevated

  • No genetic mutation was found in the genes tested
  • The patient is at elevated risk for cancer based on an analysis of additional genetic markers, personal clinical risk factors, and/or their family’s history of cancer
  • A summary of medical management guidelines will be provided based on the patient’s elevated risk

Negative

  • No genetic mutation was found in the genes tested
  • The common causes of hereditary cancer have been ruled out, but depending on family history of cancer, increased risks could still remain
  • Depending on their family history, medical management is usually based on general population screening guidelines; however, discussion with your patient can determine if there are any changes in medical management that are most appropriate for them

Variant of uncertain significance

  • A change in a gene has been identified
  • It is not yet known if the change is associated with increased cancer risk
  • Medical management based on personal and family history of cancer until more is understood about the specific change

Order Myrisk

myrisk + Cancer History Analysis = RiskScore Precision Medicine

In addition to offering accurate hereditary cancer test results, myRisk now includes riskScore for eligible women who test negative for a pathogenic mutation in a breast cancer related gene. By incorporating personal and family history with myRisk results, eligible women can receive a more comprehensive level of risk assessment to incorporate into a screening and prevention plan.

Breast Cancer riskScore

Learn More About RiskScore

What is the myRisk Management Tool?

In addition to myRisk results, the myRisk Management Tool will include riskScore results and leading society guidelines for patients who may be at or above the 20% threshold for consideration of modified medical management. Your patient’s clinical history will also be included in an easy-to-read format to provide you and your patient with as much information as possible as you form a plan together.

READY TO ORDER?

myRisk is easy to order

  • First, identify patients at risk for hereditary cancer
  • Second, fill out the Test Request Form (TRF)
  • Third, collect sample from Myriad myRisk buccal collection kit or blood collection
  • Last, receive results in your practice 7-14 day turn-around-time

Order Test Now

References

  1. Judkins T et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer. 2014
  2. Pruss D et al. Development and validations of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes; Breast Cancer Research and Treatment. 2013
  3. Morris B et al. Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm; BMC Genetics. 2016
  4. Bowles K et al. Reclassification of uncertain variants in high and moderate cancer risk genes using history weighting analysis; ACMG. 2016